Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant HPV16/18 bivalent vaccine (E. coli) long-term immunogenicity and safety in females aged 9–26 years
CTR20170689Phase 3Completed
- Sponsor
- Xiamen University
- Start
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of human papillomavirus type 16/18 bivalent vaccine in HPV16 infection (HPV16), human papillomavirus infection type 18, Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), Anogenital human papillomavirus infection, sponsored by Xiamen University. Started Jan 2019; status: completed.
02
Drugs
human papillomavirus type 16/18 bivalent vaccine
03
Conditions
HPV16 infection (HPV16)human papillomavirus infection type 18Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)Anogenital human papillomavirus infection
Beyond the preview
Go deeper on CTR20170689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170689.